Lonza is one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
PharmaCell, which generated sales of 11 million euros in 2016, was selected not only due to its commercial success, but also because of its core expertise in autologous cell and gene therapy manufacturing - which includes experience with two commercial Advanced Therapy Medicinal Products (ATMPs) licensed products.
"PharmaCell’s position in the market complements Lonza’s leadership position in the allogeneic cell manufacturing market," said Andreas Weiler, Head of Emerging Technologies at Lonza. "This acquisition broadens Lonza’s capabilities in Europe and positions Lonza as the only contract development and manufacturing organisation to offer an international cell and gene therapy manufacturing network, spanning the United States, Europe and Asia."
PharmaCell, established in 2005 when cell manufacturing was still in its infancy, has since been the manufacturer of the only two European approved commercial cell therapy products. PharmaCell has more than 6,000 m2 of GMP clean rooms, QC and other support spaces.
Alexander Vos, CEO of PharmaCell commented: “Over the last seven years, we have been able to contract many of the blue-chip cell therapy companies. I am proud of my team, which has been able to deliver high-quality GMP-manufacturing services in this emerging and challenging field.”
